Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 270

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Open access
Kuca, Bernice, Silberstein, Stephen D., Wietecha, Linda, Berg, Paul H., Dozier, Gregory, Lipton, Richard B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, Michael, Alftine, Christopher, Allaw, Mohammed, Allen, Lawrence, Ampajwala, Madhavi, Bakhtari, Ladan, Bhasker, Kala, Bird, David, Bolshoun, David, Brown, Judith, Brownstone, Paul, Bruce, Tami, Burke, Dina, Chuang, Rita, Conrady, Rickie, Davis, Bethany, Davis, Cedrice, Dawson, Mark, Desantis, Donna, Dushkin, Holly, Ellison, William, Ervin, John, Essink, Beal, Fakhouri, Ibrahim, Fiel, Thomas, Fitzgibbons, William, Francyk, David, Geisberg, Harry, Geohas, Jeff, Giep, Son, Glover, Richard, Godbole, Narendra, Grainger, William, Griffin, Carl, Halpern, Steven, Han, Michael, Hiotis, Louis, Huffman, Cynthia, Hummel, Matthew, Hurley, Donald, Inzerello, Anthony, Jagielo, Ted, Jennings, William, Kaiser, Scott, Kay, Jennifer, Khalifa, Ammar, Kirby, William, Klein, Jeffrey, Klein, Tracy, Kopp, James, Kotek, Larry, Korff, Gary, Kutner, Mark, Lending, Robert, Lentino, Joseph, Lenzmeier, Thomas, Lesch, David, Levins, Peter, Lewis, Matthew, Lowy, Adam, Lunn, Charles, Maw, Kelli, McConnehey, Brock, Mehra, Vishaal, Mehta, Praful, Meli, James, Mirza, Lubna, Molin, Clifford, Molpus, Robert, Murray, Linda, Noss, Michael, Palatnik, Mikhail, Rauzi, Frank, Razzaque, Naveed, Reynolds, Michelle, Riesenberg, Robert, Riffer, Ernie, Rodriguez, Ana, Schlosser, Daniel, Schumacher, Douglas, Severance, Randall, Shockey, Gerald, Singer, Richard, Smith, William, Stewart, Jeffrey, Stolyar, Arkadiy, Tejada, Albert, Tharenos, Leslie, Titus, John, Turner, Mark, Turner, Merle, Vallanat, Aggy, Verma, Sunil, Vollbracht, Sarah, Wilks, Kerri, Williams, Hayes, Williams, Wesley, Wolf, Thomas · 2018 · Neurology

Abstract

Objective To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Methods Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). Results Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0–3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6–3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3–2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3–2.2, p< 0.001) were free of their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity. Conclusions Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors. ClinicalTrials.gov identifier NCT02439320. Classification of evidence This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000006641

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 270

Metadata

Authors
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., Allaw, M., Allen, L., Ampajwala, M., Bakhtari, L., Bhasker, K., Bird, D., Bolshoun, D., Brown, J., Brownstone, P., Bruce, T., Burke, D., Chuang, R., Conrady, R., Davis, B., Davis, C., Dawson, M., Desantis, D., Dushkin, H., Ellison, W., Ervin, J., Essink, B., Fakhouri, I., Fiel, T., Fitzgibbons, W., Francyk, D., Geisberg, H., Geohas, J., Giep, S., Glover, R., Godbole, N., Grainger, W., Griffin, C., Halpern, S., Han, M., Hiotis, L., Huffman, C., Hummel, M., Hurley, D., Inzerello, A., Jagielo, T., Jennings, W., Kaiser, S., Kay, J., Khalifa, A., Kirby, W., Klein, J., Klein, T., Kopp, J., Kotek, L., Korff, G., Kutner, M., Lending, R., Lentino, J., Lenzmeier, T., Lesch, D., Levins, P., Lewis, M., Lowy, A., Lunn, C., Maw, K., McConnehey, B., Mehra, V., Mehta, P., Meli, J., Mirza, L., Molin, C., Molpus, R., Murray, L., Noss, M., Palatnik, M., Rauzi, F., Razzaque, N., Reynolds, M., Riesenberg, R., Riffer, E., Rodriguez, A., Schlosser, D., Schumacher, D., Severance, R., Shockey, G., Singer, R., Smith, W., Stewart, J., Stolyar, A., Tejada, A., Tharenos, L., Titus, J., Turner, M., Turner, M., Vallanat, A., Verma, S., Vollbracht, S., Wilks, K., Williams, H., Williams, W., & Wolf, T.
Venue
Neurology
Published
2018-12-11
Volume
91
Issue
24
Pages
e2222-e2232
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2901869599
Cited by
270
References
20
FWCI
26.18
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. https://app.cochat.ai/papers/10.1212/wnl.0000000000006641
The paper
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., Allaw, M., Allen, L., Ampajwala, M., Bakhtari, L., Bhasker, K., Bird, D., Bolshoun, D., Brown, J., Brownstone, P., . . . Wolf, T. (2018). Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. https://doi.org/10.1212/wnl.0000000000006641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.